These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 7408390

  • 21. Pharmacokinetics of carteolol in relation to renal function.
    Hasenfuss G, Schäfer-Korting M, Knauf H, Mutschler E, Just H.
    Eur J Clin Pharmacol; 1985; 29(4):461-5. PubMed ID: 4092726
    [Abstract] [Full Text] [Related]

  • 22. Betaxolol kinetics in hypertensive children with normal and abnormal renal function.
    Palminteri R, Assael BM, Bianchetti G, Gomeni R, Claris-Appiani A, Edefonti A, Morselli PL.
    Clin Pharmacol Ther; 1984 Feb; 35(2):141-7. PubMed ID: 6692644
    [Abstract] [Full Text] [Related]

  • 23. The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol.
    Houtzagers JJ, Streurman O, Regårdh CG.
    Br J Clin Pharmacol; 1982 Jul; 14(1):67-72. PubMed ID: 6125199
    [Abstract] [Full Text] [Related]

  • 24. Elimination of nadolol by patients with renal impairment.
    Herrera J, Vukovich RA, Griffith DL.
    Br J Clin Pharmacol; 1979 Jul; 7 Suppl 2(Suppl 2):227S-231S. PubMed ID: 37878
    [Abstract] [Full Text] [Related]

  • 25. Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol.
    Kirch W, Spahn H, Ohnhaus EE, Köhler H, Heinz U, Mutschler E.
    Biopharm Drug Dispos; 1983 Jul; 4(1):73-81. PubMed ID: 6839004
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure.
    Ruzicka H, Björkman S, Lethagen S, Sterner G.
    Pharmacol Toxicol; 2003 Mar; 92(3):137-42. PubMed ID: 12753429
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment.
    Larsson R, Liedholm H, Andersson KE, Keane MA, Henry G.
    Eur J Clin Pharmacol; 1986 Mar; 29(5):549-53. PubMed ID: 3956560
    [Abstract] [Full Text] [Related]

  • 28. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Kleinbloesem CH, van Brummelen P, van Harten J, Danhof M, Breimer DD.
    Clin Pharmacol Ther; 1985 May; 37(5):563-74. PubMed ID: 3987180
    [Abstract] [Full Text] [Related]

  • 29. A study of practolol elimination in all grades of chronic renal failure.
    Kaye CM, Kumana CR, Franklin DA, Baker LR.
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):83-8. PubMed ID: 1165145
    [Abstract] [Full Text] [Related]

  • 30. A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension.
    Wilkinson R, Stevens IM, Pickering M, Robson V, Hawkins T, Kerr DN, Harry JD.
    Br J Clin Pharmacol; 1980 Jul; 10(1):51-9. PubMed ID: 6994760
    [Abstract] [Full Text] [Related]

  • 31. Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.
    O'Connor PC, Arnold JM, Brown AN, Francis RJ, Finch MB, Galloway DB, Harron DW, McDevitt DG, Shanks RG.
    Br J Clin Pharmacol; 1985 Mar; 19(3):319-27. PubMed ID: 2859047
    [Abstract] [Full Text] [Related]

  • 32. Sotalol kinetics in renal insufficiency.
    Blair AD, Burgess ED, Maxwell BM, Cutler RE.
    Clin Pharmacol Ther; 1981 Apr; 29(4):457-63. PubMed ID: 7471612
    [Abstract] [Full Text] [Related]

  • 33. Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Salahudeen AK, Wilkinson R, McAinsh J, Bateman DN.
    Br J Clin Pharmacol; 1984 Sep; 18(3):457-60. PubMed ID: 6487486
    [Abstract] [Full Text] [Related]

  • 34. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B, Dalén E, Lindström B.
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [Abstract] [Full Text] [Related]

  • 35. Withdrawal of long-term therapy with atenolol in hypertensive patients.
    Webster J, Hawksworth GM, Barber HE, Jeffers TA, Petrie JC.
    Br J Clin Pharmacol; 1981 Aug; 12(2):211-4. PubMed ID: 7306435
    [Abstract] [Full Text] [Related]

  • 36. Food-induced reduction in bioavailability of atenolol.
    Melander A, Stenberg P, Liedholm H, Scherstén B, Wåhlin-Boll E.
    Eur J Clin Pharmacol; 1979 Nov; 16(5):327-30. PubMed ID: 520399
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of norfloxacin in chronic renal failure.
    Arrigo G, Cavaliere G, D'Amico G, Passarella E, Broccali G.
    Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):491-6. PubMed ID: 4055162
    [Abstract] [Full Text] [Related]

  • 38. The pharmacokinetics of metoprolol and its metabolites in dialysis patients.
    Seiler KU, Schuster KJ, Meyer GJ, Niedermayer W, Wassermann O.
    Clin Pharmacokinet; 1980 Sep; 5(2):192-8. PubMed ID: 7363534
    [Abstract] [Full Text] [Related]

  • 39. Effects of orange juice on the pharmacokinetics of atenolol.
    Lilja JJ, Raaska K, Neuvonen PJ.
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):337-40. PubMed ID: 15983823
    [Abstract] [Full Text] [Related]

  • 40. Response to atenolol in arterial hypertension in relation to renal function, pharmacokinetics and renin activity.
    Zech PY, Labeeuw M, Pozet N, Hadj-Aissa A, Sassard J, McAinsh J.
    Postgrad Med J; 1977 Jul; 53 Suppl 3():134-41. PubMed ID: 928260
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.